[1] |
YU SJ. Immunotherapy for hepatocellular carcinoma: Recent advances and future targets[J]. Pharmacol Ther, 2023, 244: 108387. DOI: 10.1016/j.pharmthera.2023.108387.
|
[2] |
BROWN ZJ, TSILIMIGRAS DI, RUFF SM, et al. Management of hepatocellular carcinoma: A review[J]. JAMA Surg, 2023, 158( 4): 410- 420. DOI: 10.1001/jamasurg.2022.7989.
|
[3] |
ALMEIDA AC, MAIATO H. Chromokinesins[J]. Curr Biol, 2018, 28( 19): R1131- R1135. DOI: 10.1016/j.cub.2018.07.017.
|
[4] |
BEGLEY MA, SOLON AL, DAVIS EM, et al. K-fiber bundles in the mitotic spindle are mechanically reinforced by Kif15[J]. Mol Biol Cell, 2021, 32( 22): br11. DOI: 10.1091/mbc.E20-06-0426.
|
[5] |
LUO Y, ZHANG B, XU L, et al. Downregulation of KIF15 inhibits the tumorigenesis of non-small-cell lung cancer via inactivating Raf/MEK/ERK signaling[J]. Histol Histopathol, 2022, 37( 3): 269- 285. DOI: 10.14670/HH-18-408.
|
[6] |
GE W, CHEN Y, GUO Y, et al. KIF15 upregulation promotes leiomyosarcoma cell growth via promoting USP15-mediated DEK deubiquitylation[J]. Biochem Biophys Res Commun, 2021, 570: 117- 124. DOI: 10.1016/j.bbrc.2021.07.042.
|
[7] |
TAO J, SUN G, LI Q, et al. KIF15 promotes the evolution of gastric cancer cells through inhibition of reactive oxygen species-mediated apoptosis[J]. J Cell Physiol, 2020, 235( 12): 9388- 9398. DOI: 10.1002/jcp.29743.
|
[8] |
RUMGAY H, ARNOLD M, FERLAY J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol, 2022, 77( 6): 1598- 1606. DOI: 10.1016/j.jhep.2022.08.021.
|
[9] |
SUN Y, ZHANG W, BI X, et al. Systemic therapy for hepatocellular carcinoma: Chinese consensus-based interdisciplinary expert statements[J]. Liver Cancer, 2022, 11( 3): 192- 208. DOI: 10.1159/000521596.
|
[10] |
SIEGEL RL, MILLER KD, FUCHS HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72( 1): 7- 33. DOI: 10.3322/caac.21708.
|
[11] |
Chinese Association of Liver Cancer of Chinese Medical Doctor Association. Chinese expert consensus on the whole‐course management of hepatocellular carcinoma(2023 edition)[J]. Chin J Dig Surg, 2023, 22( 7): 824- 842. DOI: 10.3760/cma.j.cn115610-20230605-00261.
中国医师协会肝癌专业委员会. 肝细胞癌全程管理中国专家共识(2023版)[J]. 中华消化外科杂志, 2023, 22( 7): 824- 842. DOI: 10.3760/cma.j.cn115610-20230605-00261.
|
[12] |
ZHANG S, TU Q, QIAN X, et al. Deficiency of Kif15 gene inhibits tumor growth due to host CD8+T lymphocytes increase[J]. Biochem Biophys Res Commun, 2023, 655: 110- 117. DOI: 10.1016/j.bbrc.2023.03.006.
|
[13] |
VANNESTE D, FERREIRA V, VERNOS I. Chromokinesins: localization-dependent functions and regulation during cell division[J]. Biochem Soc Trans, 2011, 39( 5): 1154- 1160. DOI: 10.1042/BST0391154.
|
[14] |
HE Z, WANG J, XU J, et al. Dynamic regulation of KIF15 phosphorylation and acetylation promotes focal adhesions disassembly in pancreatic cancer[J]. Cell Death Dis, 2022, 13( 10): 896. DOI: 10.1038/s41419-022-05338-y.
|
[15] |
SUN RF, HE N, ZHANG GY, et al. Combined inhibition of KIF11 and KIF15 as an effective therapeutic strategy for gastric cancer[J]. Curr Cancer Drug Targets, 2023, 23( 4): 293- 306. DOI: 10.2174/1568009622666220616122846.
|
[16] |
QUAN G, XU J, WANG J, et al. KIF15 is essential for USP10-mediated PGK1 deubiquitination during the glycolysis of pancreatic cancer[J]. Cell Death Dis, 2023, 14( 2): 137. DOI: 10.1038/s41419-023-05679-2.
|
[17] |
WANG L, ZHANG X, LIU J, et al. Kinesin family member 15 can promote the proliferation of glioblastoma[J]. Math Biosci Eng, 2022, 19( 8): 8259- 8272. DOI: 10.3934/mbe.2022384.
|
[18] |
MI J, MA S, CHEN W, et al. Integrative pan-cancer analysis of KIF15 reveals its diagnosis and prognosis value in nasopharyngeal carcinoma[J]. Front Oncol, 2022, 12: 772816. DOI: 10.3389/fonc.2022.772816.
|
[19] |
GAO L, ZHANG W, ZHANG J, et al. KIF15-mediated stabilization of AR and AR-V7 contributes to enzalutamide resistance in prostate cancer[J]. Cancer Res, 2021, 81( 4): 1026- 1039. DOI: 10.1158/0008-5472.CAN-20-1965.
|
[20] |
CHAN YT, LIN RJ, WANG YH, et al. The interplay between IGF-1R signaling and Hippo-YAP in breast cancer stem cells[J]. Cell Commun Signal, 2023, 21( 1): 81. DOI: 10.1186/s12964-023-01088-2.
|
[21] |
TIAN LY, SMIT DJ, JÜCKER M. The role of PI3K/AKT/mTOR signaling in hepatocellular carcinoma metabolism[J]. Int J Mol Sci, 2023, 24( 3): 2652. DOI: 10.3390/ijms24032652.
|
[22] |
LIU M, HUANG XD, HAN Z, et al. Effect of cadherin-17 on proliferation and apoptosis of colorectal cancer cells and its PI3K/AKT/m TOR signaling pathway regulatory mechanism[J]. J Jilin Univ(Med Edit), 2023, 49( 4): 1008- 1017. DOI: 10.13481/j.1671-587X.20230423.
刘蒙, 黄晓东, 韩峥, 等. 钙黏蛋白17对结直肠癌细胞增殖和凋亡的影响及其PI3K/AKT/mTOR信号通路调节机制[J]. 吉林大学学报(医学版), 2023, 49( 4): 1008- 1017. DOI: 10.13481/j.1671-587X.20230423.
|
[23] |
JIANG Q, GUAN Y, ZHENG J, et al. TBK1 promotes thyroid cancer progress by activating the PI3K/Akt/mTOR signaling pathway[J]. Immun Inflamm Dis, 2023, 11( 3): e796. DOI: 10.1002/iid3.796.
|
[24] |
LI Y, WANG S, JIN K, et al. UHMK1 promotes lung adenocarcinoma oncogenesis by regulating the PI3K/AKT/mTOR signaling pathway[J]. Thorac Cancer, 2023, 14( 12): 1077- 1088. DOI: 10.1111/1759-7714.14850.
|
[25] |
CHEN J, LIU F, WU J, et al. Effect of STK3 on proliferation and apoptosis of pancreatic cancer cells via PI3K/AKT/mTOR pathway[J]. Cell Signal, 2023, 106: 110642. DOI: 10.1016/j.cellsig.2023.110642.
|